You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

 

Online download statistics by month:

Online download statistics by month: January 2024 to July 2025

AbstractFullPdf
Jan 2024466471210
Feb 202416616786
Mar 202410911396
Apr 2024929373
May 2024717358
Jun 2024868947
Jul 2024697140
Aug 20247877118
Sep 2024646538
Oct 2024616138
Nov 2024545532
Dec 2024505130
Jan 2025838445
Feb 202515215229
Mar 2025606029
Apr 2025747442
May 2025696941
Jun 2025454630
Jul 2025110
Total185018721082